MP 124

Drug Profile

MP 124

Alternative Names: MP-124

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Class
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Stroke

Most Recent Events

  • 31 Jul 2015 MP 124 is still in phase I trials for Stroke in USA
  • 31 Jul 2015 Discontinued - Phase-I for Stroke in Canada (IV)
  • 14 Oct 2009 Phase-I clinical trials in Stroke in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top